Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Loic Ysebaert

17PUBLICATIONS
112CO-AUTHORS
Tumour immunologyHaematological tumoursEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

Sort by Publication Date:
|Jun 23, 2026
Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study.

|Oct 30, 2025
Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population.

Paolo Ghia, Loic Ysebaert, Ann Janssens

|Apr 26, 2025
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah

|Jan 22, 2025
Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Sarka Pavlova, Jitka Malcikova, Lenka Radova

|Jul 22, 2024
New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.

Sarah Cadot, Chloe Audebert, Charlotte Dion

|Feb 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Vincent Camus, Catherine Thieblemont, Philippe Gaulard

Pageof 3

Frequent Collaborators

3 joint publications

Franck Morschhauser

3 joint publications

Emmanuel Bachy

3 joint publications

René-Olivier Casasnovas

2 joint publications

Virginie Nerich

2 joint publications

Michel Henry-Amar

2 joint publications

Gilles Salles

2 joint publications

Vincent Camus

2 joint publications

Catherine Thieblemont

2 joint publications

Won Seog Kim

2 joint publications

Alejandro Martín García-Sancho

Frequent Collaborators

3 joint publications

Franck Morschhauser

3 joint publications

Emmanuel Bachy

3 joint publications

René-Olivier Casasnovas

2 joint publications

Virginie Nerich